Latest Announcements
Ladenburg Thalmann Acts as Exclusive Financial Advisor to Spero Therapeutics, Inc. (Nasdaq: SPRO) in its $125 Million Revenue Interest Financing
Transaction Information Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas...
Ladenburg Thalmann acts as Lead Bookrunner for NewLake Capital Partners Inc. on its Initial Public Offering of $101.6 million
Transaction Information New Canaan, CT - NewLake Capital Partners, Inc. (OTCQX:NLCP) (the "Company"), a leading provider of real estate capital to state-licensed cannabis operators, announced that it has closed...
Ladenburg Thalmann Acts as Exclusive Financial Advisor to Aerpio Pharmaceuticals, Inc. (ARPO) in its Merger With Aadi Biosciences, Inc.
On August 26, 2021, Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) announced the completion of its merger with Aadi Biosciences, Inc. Concurrent with the closing of the transaction, an investor syndicate led by Acuta...
Ladenburg Thalmann Acts as Co-Manager for Immunic, Inc. (IMUX) in its $45.0 Million Follow-On Offering
Transaction Information Immunic, Inc. (Nasdaq: IMUX), announced the closing of its previously announced public offering of 4,500,000 shares of common stock at a public offering price of $10.00 per share. Immunic...
Ladenburg Thalmann Acts as Lead Book-Running Manager for Applied UV, Inc. (AUVI) in its $12.0 Million Series A Cumulative Perpetual Preferred Stock Offering
Transaction Information Applied UV, Inc. (NASDAQ: AUVI) announced the closing of its underwritten registered public offering of 480,000 shares of 10.5% Series A Cumulative Perpetual Preferred Stock, with...
Ladenburg Thalmann Acts as Co-Manager for Celsius Holdings, Inc. (CELH) in its $461.9 Million Follow-On Offering
Transaction Information Celsius Holdings, Inc. (NASDAQ: CELH), closed its previously announced public offering of 7,391,408 shares of common stock, consisting of 6,257,455 shares of common stock offered by...
Ladenburg Thalmann Acts as Sole Book-Running Manager for electroCore, Inc. (ECOR) in its $20.7 Million Follow-On Offering
Transaction Information electroCore, Inc. (NASDAQ: ECOR) announced the closing of its previously announced underwritten public offering of 20,700,000 shares of its common stock at a price to the public of $1.00...
Ladenburg Thalmann Acts as Co-Manager for ABC Pharma Co, Inc. (CELH) in its $461.9 Million Follow-On Offering
Transaction Information Celsius Holdings, Inc. (NASDAQ: CELH), closed its previously announced public offering of 7,391,408 shares of common stock, consisting of 6,257,455 shares of common stock offered by...
Ladenburg Thalmann Acts as Exclusive Placement Agent for Jaguar Health, Inc. (JAGX) in its $10.8 Million Registered Direct Offering
Transaction Information Jaguar Health, Inc. (NASDAQ: JAGX) announced it has entered into a securities purchase agreement with North American institutional investors for the purchase and sale of 7,647,000 shares...
Ladenburg Thalmann Acts as Co-Manager for SeaSpine Holdings Corporation (SPNE) in its $100.9 Million Follow-On Offering
Transaction Information SeaSpine Holdings Corporation (NASDAQ: SPNE) announced the pricing of its previously announced underwritten public offering of 5,175,000 shares of its common stock at a public offering...
Ladenburg Thalmann Acts as Exclusive Placement Agent for Immunome, Inc. (IMNM) in its $27.0 Million Private Placement
Transaction Information Immunome, Inc. (NASDAQ: IMNM) announced it has entered into a definitive securities purchase agreement for the sale of its equity securities in a private placement with certain accredited...
Ladenburg Thalmann Acts as Co-Manager for BrainsWay Ltd. (BWAY) in its $45.2 Million Follow-On Offering
Transaction Information BrainsWay Ltd. (NASDAQ: BWAY) announced the closing of its previously announced underwritten public offering of 5,315,300 American Depositary Shares ("ADSs"), upsized to include 693,300...